Lyra Therapeutics Inc (NASDAQ:LYRA) shares, rose in value on Thursday, February 13, with the stock price up by 6.87% to the previous day’s close as strong demand from buyers drove the stock to $0.21.
Actively observing the price movement in the last trading, the stock closed the session at $0.20. Referring to stock’s 52-week performance, its high was $6.79, and the low was $0.16. On the whole, LYRA has fluctuated by 10.99% over the past month.
With the market capitalization of Lyra Therapeutics Inc currently standing at about $13.74 million, investors are eagerly awaiting this quarter’s results, scheduled for in March.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 206k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LYRA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LYRA currently trading nearly 10.96% and 8.16% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 63.18, while the 7-day volatility ratio is showing 8.41% which for the 30-day chart, stands at 7.22%. Furthermore, Lyra Therapeutics Inc (LYRA)’s beta value is -0.14, and its average true range (ATR) is 0.02.
A comparison of Lyra Therapeutics Inc (LYRA) with its peers suggests the former has fared considerably weaker in the market. LYRA showed an intraday change of 6.87% in last session, and over the past year, it shrunk by -95.69%%.
Data on historical trading for Lyra Therapeutics Inc (NASDAQ:LYRA) indicates that the trading volumes over the past 3 months, they’ve averaged 1.83 million. According to company’s latest data on outstanding shares, there are 65.46 million shares outstanding.
Nearly 17.98% of Lyra Therapeutics Inc’s shares belong to company insiders and institutional investors own 44.82% of the company’s shares. The stock has risen by 1.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LYRA stock heading into the next quarter.
